ALEAF:OTC-Aleafia Health Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.28

Change

0.00 (0.00)%

Market Cap

USD 0.09B

Volume

0.42M

Avg Analyst Target

USD 5.81 (+1,975.00%)

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aleafia Health Inc. operates as an integrated cannabis health and wellness services company in Canada and internationally. It produces a portfolio of products, including dried flower and pre-rolls, as well as oil drops and capsules, oral sprays, and cannabis-infused sublingual strips. The company offers its products under the Kin Slips, Emblem, and Symbl brands. It also operates a network of 25 medical cannabis clinics under the Canabo Clinics brand name; and education centers. The company was incorporated in 2007 and is headquartered in Concord, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD100.34B 31.09 19.81
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD99.95B 31.01 19.81
TKPHF Takeda Pharmaceutical Company ..

N/A

USD54.34B 13.68 0.08
ESALF Eisai Co. Ltd

N/A

USD23.79B 43.50 0.18
ESALY Eisai Co. Ltd

N/A

USD22.26B 40.69 0.18
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD21.71B 22.16 2.72
SGIOF Shionogi & Co. Ltd

N/A

USD20.65B 18.71 0.11
SGIOY Shionogi & Co. Ltd

N/A

USD20.51B 18.58 0.11
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
TEVJF Teva Pharmaceutical Industries..

N/A

USD10.28B 900.00 16.02

ETFs Containing ALEAF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.77% 35% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.77% 35% F 22% F
Trailing 12 Months  
Capital Gain -27.98% 30% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.98% 30% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -15.08% 23% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.08% 23% F 6% F
Risk Return Profile  
Volatility (Standard Deviation) 44.91% 73% C 53% F
Risk Adjusted Return -33.58% 23% F 11% F
Market Capitalization 0.09B 77% C+ 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.50 86% B 95% A
Price/Book Ratio 0.70 78% C+ 77% C+
Price / Cash Flow Ratio -12.14 78% C+ 80% B-
EV/EBITDA 34.85 13% F 12% F
Management Effectiveness  
Return on Equity -89.28% 33% F 13% F
Return on Invested Capital -13.32% 51% F 23% F
Return on Assets -10.06% 60% D- 31% F
Debt to Equity Ratio 21.04% 38% F 55% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.27 44% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector